Drug
Leronlimab clinical trials
Also written PRO 140.
- studies test it
- 25
- open now
- 2
- in phase 3
- 7
- first study started
- 2004
Keep track of what changes. Save the leronlimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
24 studies that test it; most in 2020 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 3 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 21
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 6
CytoDyn, Inc. (19) · Hospital Israelita Albert Einstein (2) · Drexel University (2) · City of Hope Medical Center (1) · Weill Medical College of Cornell University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses leronlimab is read from its arms, and is right about nine times in ten.
Testing it · 25
- CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP TrialNot yet recruitingPhase 1City of Hope Medical CenterNCT07842965Written as Leronlimab
- Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's DiseaseRecruitingPhase 2Weill Medical College of Cornell UniversityNCT07553338Written as Leronlimab (700mg)
- CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched RegimenActive, not recruitingPhase 2CytoDyn, Inc.NCT06699836Written as 350 mg leronlimab
- Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 InfectionCompletedPhase 2/3CytoDyn, Inc.NCT02859961Written as PRO 140 (350 mg)
- Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid TumorsCompletedPhase 2CytoDyn, Inc.NCT04504942Written as Leronlimab
- An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label StudyTerminatedPhase 2/3CytoDyn, Inc.NCT02990858Written as PRO 140
- An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 StudyTerminatedPhase 2/3CytoDyn, Inc.NCT05271370Written as PRO 140 350
- Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19CompletedPhase 2CytoDyn, Inc.NCT04347239Written as Leronlimab (700mg)
- An Extension of Protocol PRO 140_CD01 StudyTerminatedPhase 2CytoDyn, Inc.NCT02355184Written as PRO 140 350mg weekly subcutaneous (SC) injection.
- PRO 140 in Treatment-Experienced HIV-1 SubjectsCompletedPhase 2/3CytoDyn, Inc.NCT03902522Written as PRO 140
- Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBCTerminatedPhase 1/2CytoDyn, Inc.NCT03838367Written as 350 mg leronlimab
- Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19CompletedPhase 2CytoDyn, Inc.NCT04678830Written as Leronlimab (700mg)
- A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell TransplantationTerminatedPhase 2CytoDyn, Inc.NCT02737306Written as PRO 140
- Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 InfectionCompletedPhase 2CytoDyn, Inc.NCT02175680Written as PRO 140
- Safety and Tolerability of PRO 140 in HIV Uninfected Male VolunteersCompletedPhase 1CytoDyn, Inc.NCT00110591Written as PRO 140
- Leronlimab (PRO 140) in Patients With Nonalcoholic SteatohepatitisCompletedPhase 2CytoDyn, Inc.NCT04521114Written as leronlimab 700 mg
- Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19CompletedPhase 2CytoDyn, Inc.NCT04343651Written as Leronlimab (700mg)
- Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140CompletedPhase 2/3CytoDyn, Inc.NCT02483078Written as PRO 140
- Leronlimab in Moderately Ill Patients With COVID-19 PneumoniaSuspendedPhase 3Hospital Israelita Albert EinsteinNCT04901676Written as Leronlimab
- Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane OxygenationSuspendedPhase 3Hospital Israelita Albert EinsteinNCT04901689Written as Leronlimab
Codes
What other systems call leronlimab · ClinicalTrials.gg INT004303
- MeSH (NLM) C420063leronlimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Y1J4NP8FF0LERONLIMABConfirmed FDA, NLM
- NCI Thesaurus C137824LeronlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C420063 | leronlimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Y1J4NP8FF0 | LERONLIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C137824 | Leronlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.